AxoGen Stock

AxoGen Dividend

Dividend of AxoGen (AXGN) as of Aug 5, 2026.

Dividend

0.00USD

Dividend yield

2.20 %

Last updated:

How much dividend does AxoGen 2026 pay?

According to the latest status from August 2026, AxoGen paid a total of 0.00 USD per share in dividends within the last 12 months. With the current AxoGen price of 45.40 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

AxoGen currently offers a dividend yield of about 2.20%.

Historical AxoGen Dividends

PaydateDividend
2/27/20101.00USD
3/23/20050.06USD

Is the AxoGen Dividend Safe?

AxoGen has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

AxoGen dividend payout ratio

In 2025, AxoGen had a payout ratio of 0.00%. The payout ratio indicates the percentage of the company's profits that AxoGen distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
0.00 %
Jan 1, 2022
0.00 %
Jan 1, 2023
0.00 %
Jan 1, 2024
0.00 %
Jan 1, 2025
0.00 %
Jan 1, 2026 (e)
0.00 %
Jan 1, 2027 (e)
0.00 %
Jan 1, 2028 (e)
0.00 %

Dividend Details

Understanding AxoGen's Dividend Distributions

AxoGen’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining AxoGen's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

AxoGen's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in AxoGen’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AxoGen stock

The current dividend yield of AxoGen is 2.20 %.

AxoGen paid dividends every year for the past 0 years.

AxoGen is assigned to the 'Health' sector.

To receive the latest dividend of AxoGen from amounting to 1 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of AxoGen are distributed in USD.

Dividend calendar 2026
Access this data via the Eulerpool API

All Key Metrics — AxoGen